Zymeworks Inc. Common Shares (ZYME): Price and Financial Metrics

Zymeworks Inc. Common Shares (ZYME): $5.82

0.65 (+12.57%)

POWR Rating

Component Grades













Add ZYME to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where ZYME ranks best; there it ranks ahead of 51.86% of US stocks.
  • ZYME's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • ZYME ranks lowest in Stability; there it ranks in the 5th percentile.

ZYME Stock Summary

  • With a year-over-year growth in debt of 278.23%, Zymeworks Inc's debt growth rate surpasses 95.7% of about US stocks.
  • As for revenue growth, note that ZYME's revenue has grown -31.5% over the past 12 months; that beats the revenue growth of only 5.32% of US companies in our set.
  • The volatility of Zymeworks Inc's share price is greater than that of 96.98% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Zymeworks Inc are ARDS, CDTX, IVA, XCUR, and AUTL.
  • ZYME's SEC filings can be seen here. And to visit Zymeworks Inc's official web site, go to www.zymeworks.com.

ZYME Valuation Summary

  • In comparison to the median Healthcare stock, ZYME's price/earnings ratio is 118.9% lower, now standing at -6.9.
  • ZYME's EV/EBIT ratio has moved up 2.5 over the prior 53 months.
  • ZYME's EV/EBIT ratio has moved up 2.5 over the prior 53 months.

Below are key valuation metrics over time for ZYME.

Stock Date P/S P/B P/E EV/EBIT
ZYME 2021-08-31 73.8 4.8 -6.9 -5.9
ZYME 2021-08-30 72.8 4.7 -6.8 -5.8
ZYME 2021-08-27 73.5 4.7 -6.9 -5.8
ZYME 2021-08-26 71.5 4.6 -6.7 -5.7
ZYME 2021-08-25 72.9 4.7 -6.8 -5.8
ZYME 2021-08-24 73.8 4.8 -6.9 -5.9

ZYME's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZYME has a Quality Grade of D, ranking ahead of 18.34% of graded US stocks.
  • ZYME's asset turnover comes in at 0.047 -- ranking 324th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ZYME's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.047 1 -1.423
2021-06-30 0.040 1 -1.267
2021-03-31 0.057 1 -0.902
2020-12-31 0.066 1 -0.661
2020-09-30 0.046 1 -0.832
2020-06-30 0.060 1 -0.772

ZYME Stock Price Chart Interactive Chart >

Price chart for ZYME

ZYME Price/Volume Stats

Current price $5.82 52-week high $39.41
Prev. close $5.17 52-week low $4.56
Day low $5.11 Volume 2,788,300
Day high $6.07 Avg. volume 1,589,165
50-day MA $6.22 Dividend yield N/A
200-day MA $16.88 Market Cap 336.23M

Zymeworks Inc. Common Shares (ZYME) Company Bio

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company was founded in 2003 and is based in Vancouver, BC.

ZYME Latest News Stream

Event/Time News Detail
Loading, please wait...

ZYME Latest Social Stream

Loading social stream, please wait...

View Full ZYME Social Stream

Latest ZYME News From Around the Web

Below are the latest news stories about Zymeworks Inc that investors may wish to consider to help them evaluate ZYME as an investment opportunity.

Zymeworks Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Zymeworks Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 25, 2022

Zymeworks Inc. (ZYME) CEO Kenneth Galbraith on Q4 2021 Results - Earnings Call Transcript

Start Time: 16:30 End Time: 17:19 Zymeworks Inc. (ZYME) Q4 2021 Earnings Conference Call February 24, 2022, 16:30 PM ET Company Participants Kenneth Galbraith - Chair and CEO Chris Astle - SVP and CFO Neil Klompas - COO Neil Josephson - CMO Jack Spinks - Manager of IR Conference Call...

SA Transcripts on Seeking Alpha | February 25, 2022

Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results

VANCOUVER, British Columbia & SEATTLE, February 24, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2021 and provided a summary of recent business highlights.

Yahoo | February 24, 2022

Zymeworks Q4 2021 Earnings Preview

Zymeworks (NYSE:ZYME) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$1.13 (-82.3% Y/Y) and the consensus…

Seeking Alpha | February 23, 2022

Earnings Preview: Zymeworks Inc. (ZYME) Q4 Earnings Expected to Decline

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Read More 'ZYME' Stories Here

ZYME Price Returns

1-mo 8.99%
3-mo -18.94%
6-mo -70.62%
1-year -80.35%
3-year -68.14%
5-year -55.37%
YTD -64.49%
2021 -65.32%
2020 3.96%
2019 209.67%
2018 93.41%
2017 N/A

Continue Researching ZYME

Here are a few links from around the web to help you further your research on Zymeworks Inc's stock as an investment opportunity:

Zymeworks Inc (ZYME) Stock Price | Nasdaq
Zymeworks Inc (ZYME) Stock Quote, History and News - Yahoo Finance
Zymeworks Inc (ZYME) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8557 seconds.